25 Christopher Columbus Drive, STE 5403, Jersey City, NJ 07302 646-887-7984
The search for effective non-opioid analgesics is a global priority due to the risks associated with opioid use, including dependence and adverse side effects. One promising candidate is neridronate, a third-generation bisphosphonate traditionally used to treat bone disorders. Recent research suggests that neridronate may also offer significant pain relief, positioning it as a potential non-opioid analgesic.
Neridronate belongs to the bisphosphonate class of drugs, which primarily act by inhibiting bone resorption. However, its effects appear to extend beyond bone metabolism. Studies have suggested that neridronate reduces inflammation in bone marrow lesions and modulates pain pathways, particularly in conditions involving abnormal bone turnover and neuroinflammation. This dual action makes it especially relevant in chronic pain syndromes linked to skeletal abnormalities 1,2.
A growing body of clinical research has evaluated neridronate’s analgesic efficacy. One randomized controlled trial demonstrated that intramuscular neridronate significantly reduced pain in patients with Complex Regional Pain Syndrome type 1 (CRPS-1), a condition that is notoriously difficult to treat. In general, long-term follow-up studies have indicated that these benefits can persist for up to a year, with continued improvements in pain and functional outcomes. Beyond CRPS, neridronate has shown analgesic benefits in other conditions, such as for acute painful knee osteoarthritis or osteoporosis, among others 3–8.
One of the most important advantages of neridronate is its non-opioid mechanism. It avoids risks such as addiction, respiratory depression, and tolerance. Clinical trials have reported that neridronate is generally well tolerated, with no serious drug-related adverse events in many studies. In addition, its ability to address underlying pathological processes (such as bone inflammation) means it may provide more sustained relief in certain conditions compared to drugs that only mask pain symptoms 9–11.
Despite promising results, several limitations remain. In general, most studies have focused on specific conditions like CRPS and osteoarthritis, meaning that its use cannot yet be generalized to broader analgesic applications. Sample sizes in trials are often relatively small, and more large-scale, multi-center studies are needed to confirm efficacy across more populations. Furthermore, while short- to medium-term outcomes are encouraging, long-term effectiveness and optimal dosing regimens require further investigation. Researchers are also exploring how early intervention with neridronate may influence outcomes in chronic pain conditions 12–15.
As the medical community continues to prioritize opioid-sparing approaches, neridronate may emerge as an important tool in the evolving landscape of pain management.
Overall, current research highlights neridronate as a promising non-opioid analgesic, particularly in conditions involving bone and inflammatory pain.
References
1. Neridronic Acid – an overview | ScienceDirect Topics. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/neridronic-acid.
2. Pharmacology of bisphosphonates – UpToDate. https://www.uptodate.com/contents/pharmacology-of-bisphosphonates.
3. Chen, Q., Shen, P., Zhang, B., Chen, Y. & Zhen, C. The role of neridronate in the management of osteoporosis: A meta-analysis. Adv Clin Exp Med 33, 5–12 (2024). DOI: 10.17219/acem/162921
4. Gatti, D., Rossini, M., Viapiana, O., Idolazzi, L. & Adami, S. Clinical development of neridronate: potential for new applications. Ther Clin Risk Manag 9, 139–147 (2013). DOI: 10.2147/TCRM.S35788
5. Grünenthal GmbH. Open-Label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS). https://clinicaltrials.gov/study/NCT02972359 (2019).
6. Ambros Therapeutics, Inc. A Randomized, Triple-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Intravenous AMBTX-01 (Neridronate) for Treatment of Complex Regional Pain Syndrome Type 1 (CRPS-RISE). https://clinicaltrials.gov/study/NCT07210515 (2026).
7. Varenna, M. et al. Long-term efficacy and safety of neridronate treatment in patients with complex regional pain syndrome type 1: a pre-specified, open-label, extension study. Ther Adv Musculoskelet Dis 14, 1759720X221142274 (2022). DOI: 10.1177/1759720X221142274
8. Varenna, M., Zucchi, F., Failoni, S., Becciolini, A. & Berruto, M. Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study. Rheumatology (Oxford) 54, 1826–1832 (2015). DOI: 10.1093/rheumatology/kev123
9. Iolascon, G. & Moretti, A. The Rationale for Using Neridronate in Musculoskeletal Disorders: From Metabolic Bone Diseases to Musculoskeletal Pain. Int J Mol Sci 23, 6921 (2022). DOI: 10.3390/ijms23136921
10. White, P. F. What are the advantages of non-opioid analgesic techniques in the management of acute and chronic pain? Expert Opinion on Pharmacotherapy 18, 329–333 (2017). DOI: 10.1080/14656566.2017.1289176
11. Bohringer, C., Astorga, C. & Liu, H. The Benefits of Opioid Free Anesthesia and the Precautions Necessary When Employing It. Transl Perioper Pain Med 7, 152–157 (2020).
12. Zhu, H. et al. Efficacy and Safety of Pharmacological Treatment in Patients with Complex Regional Pain Syndrome: A Systematic Review and Meta-Analysis. Pharmaceuticals 17, 811 (2024). DOI: 10.3390/ph17060811
13. Duong, S., Bravo, D., Todd, K. J., Finlayson, R. J. & Tran, D. Q. Treatment of complex regional pain syndrome: an updated systematic review and narrative synthesis. Can J Anesth/J Can Anesth 65, 658–684 (2018). DOI: 10.1007/s12630-018-1091-5
14. Shim, H., Rose, J., Halle, S. & Shekane, P. Complex regional pain syndrome: a narrative review for the practising clinician. British Journal of Anaesthesia 123, e424–e433 (2019). DOI: 10.1016/j.bja.2019.03.030
15. Shekarsarai, C., McQuibban, N. A. & Gullick, N. The Analgesic Efficacy of Therapies Used for Complex Regional Pain Syndrome: A Systematic Review. Cureus 17, e91697. DOI: 10.7759/cureus.91697

